



Proteome Sciences plc
(the “Company” or the “Group”)

Option Awards

Proteome Sciences plc (AIM:PRM) announces the award of 18,160,000 nominal cost options (“Options”) over ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”) to certain executive directors on 3 April 2017 (the “Award”) as detailed below. The Options represent 6.17% of the current issued share capital of the Company and lapse on 3 April 2027 (“Lapse Date”).

Director	Current options Held	New Unapproved Options	New EMI Options	Total Options Held	Percentage of Issued Share Capital	Vesting Date
Jeremy Haigh	Nil	4,000,000	5,000,000	9,000,000	3.1%	01 June 2019
Ian Pike	165,583	Nil	3,750,000	3,915,583	1.3%	03 April 2020
Richard Dennis	Nil	Nil	3,250,000	3,250,000	1.1%	03 April 2020
Geoff Ellis	300,000	2,160,000	Nil	2,460,000	0.8%	03 April 2020
TOTAL	465,583	6,160,000	12,000,000	18,625,583		

The Options will vest subject to the holders remaining employed until the vesting date and the satisfaction of the following performance requirements (“Performance Criteria”) relating to the growth in the Company’s share price, as quoted on the London Stock Exchange:

- i. One third of the total Options awarded will vest if the Company’s closing share price over a 5-day period attains 7p at any time after the Vesting Date but before the Lapse Date (the “Exercise Period”);
- ii. A further one third of the total Options awarded will vest if the Company’s closing share price over a 5-day period attains 9p at any time during the Exercise Period; and
- iii. The final one third of the total Options awarded will vest if the Company’s closing share price over a 5-day period attains 11p at any time during the Exercise Period.

Once the Options have vested in accordance with the Performance Criteria, participants can exercise their Options at any time during the period commencing from the Vesting Date and ending on the Lapse Date.

Following the Award, the Company now has 19,526,548 options over Ordinary Shares outstanding representing 6.63% of the current issued share capital of the Company.

For further information:

Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer
Geoff Ellis, Finance Director

Tel: +44 (0)1932 865065

finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson
 Tony Quirke (broking)

Tel: +44 (0)20 7220 0500

IFC Advisory (Financial PR and IR)

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0) 203 053 8761

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant[®], TMTcalibrator[™]) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services[™] division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Jeremy Haigh
2.	Reason for the Notification	
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Proteome Sciences plc
b)	LEI	n/a
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	Options over Ordinary Shares of 1p each
	Identification code	GB0003104196
b)	Nature of the transaction	Award of options
c)	Price(s) and volume(s)	4,000,000 Unapproved Options 5,000,000 EMI Options
d)	Aggregated information:	
	- Aggregated volume	9,000,000 Options over Ordinary Shares of 1p each
	- Price	
e)	Date of the transaction	3 April 2017
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1. Details of the person discharging managerial responsibilities / person closely associated
 - a) Name Ian Pike
2. Reason for the Notification
 - a) Position/status Chief Scientific Officer
 - b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name Proteome Sciences plc
 - b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 - a) Description of the Financial instrument, type of instrument Options over Ordinary Shares of 1p each
Identification code GB0003104196
 - b) Nature of the transaction Award of Options
 - c) Price(s) and volume(s) 3,750,000 EMI Options
 - d) Aggregated information:
 - Aggregated volume 3,750,000 Options over Ordinary Shares of 1p each
 - Price
 - e) Date of the transaction 3 April 2017
 - f) Place of the transaction London Stock Exchange, AIM Market (XLON)

1. Details of the person discharging managerial responsibilities / person closely associated
 - a) Name Richard Dennis
2. Reason for the Notification
 - a) Position/status Chief Commercial Officer
 - b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name Proteome Sciences plc
 - b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 - a) Description of the Financial instrument, type of instrument Options over Ordinary Shares of 1p each
Identification code GB0003104196
 - b) Nature of the transaction Award of Options
 - c) Price(s) and volume(s) 3,250,000 EMI Options
 - d) Aggregated information:
 - Aggregated volume 3,250,000 Options over Ordinary Shares of 1p each
 - Price
 - e) Date of the transaction 3 April 2017
 - f) Place of the transaction London Stock Exchange, AIM Market (XLON)

1. Details of the person discharging managerial responsibilities / person closely associated
 - a) Name Geoff Ellis
2. Reason for the Notification
 - a) Position/status Finance Director
 - b) Initial notification/Amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name Proteome Sciences plc
 - b) LEI n/a
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 - a) Description of the Financial instrument, type of instrument Ordinary Shares of 1p each
 Identification code GB0003104196
 - b) Nature of the transaction Award of Options
 - c) Price(s) and volume(s) 2,160,000 Unapproved Options
 - d) Aggregated information:
 - Aggregated volume 2,160,000 Options over Ordinary Shares of 1p each
 - Price
- e) Date of the transaction 3 April 2017
- f) Place of the transaction London Stock Exchange, AIM Market (XLON)